# US 2026/0306713 A1 · Decellularized adipose biomaterial and method for preparing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306713 A1
- Document ID: US20260306713A1
- Status: Published application
- Kind: A1
- Application number: 19/481,349
- Filed: 2024-04-30
- Published: 2026-10-08
- Earliest claimed: 2023-05-04
- Assignees: Shanghai Sondray Biotechnology Co., Ltd.
- Applicants: Shanghai Sondray Biotechnology Co., Ltd.
- Inventors: Chengran YANG; Wenjie ZHANG
- Web page: https://patentgrep.com/patent/US20260306713A1

## CPC

- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A decellularized adipose biomaterial is a cell-free extract derived from an adipose tissue and a biomaterial acquired by mixing a liquid cell-free fat extract of a fat mixture acquired by washing, crushing and separating an adipose tissue with a solid cell-free fat extract acquired from a fat mixture by decellularization, delipidation and other processes. The decellularized adipose biomaterial prepared by mixing has long-acting tissue repair and tissue regeneration-guiding capability, and can be used in the fields of soft tissue defect repair, shaping and filling, and the like.

## Claims

### Claim 1

A decellularized adipose biomaterial, wherein, the decellularized adipose biomaterial is prepared by a method comprising the steps of:
(1) providing an adipose tissue raw material, crushing the adipose tissue raw material, and rinsing it to obtain a rinsed adipose tissue;
(2) subjecting the rinsed adipose tissue to centrifugation to obtain a layered mixture, removing the upper oil layer and the lower aqueous layer, and collecting the intermediate layer;
(3) subjecting the intermediate layer to emulsification to obtain an emulsified fat mixture;
(4) subjecting the emulsified fat mixture to centrifugation to obtain an intermediate liquid layer, which is the initial adipose extract A, and an intermediate solid layer, which is the initial adipose extract B;
(5) subjecting the initial adipose extract A to filtration and sterilization to obtain cell-free fat extract C;
(6) subjecting the initial adipose extract B to emulsification treatment, disinfection treatment, decellularization treatment, and delipidation treatment in sequence to obtain cell-free fat extract D;
(7) mixing the cell-free fat extract C with D and post-processing to obtain the decellularized adipose biomaterial.

### Claim 2 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (3), the emulsification is mechanical emulsification; wherein, the mechanical emulsification is carried out by repeatedly push-pull mixing with a syringe.

### Claim 3 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (3), the emulsification comprises breaking and emulsifying by a tissue homogenizer.

### Claim 4 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (4), after centrifugation, the emulsified fat mixture is layered into 4 layers, with the first layer being an oil layer, the second layer being a residual adipose tissue layer (i.e. the intermediate solid layer), the third layer being a liquid layer (i.e. the intermediate liquid layer), and the fourth layer being a cell/tissue fragment precipitation layer.

### Claim 5 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein step (6) comprises:
(6a) subjecting the initial adipose extract B to emulsification treatment, and post-processing to obtain a solid content;
(6b) subjecting the solid content obtained in step (6a) to disinfection treatment, and post-processing to obtain a solid content;
(6c) subjecting the solid content obtained in step (6b) to decellularization treatment, and post-processing to obtain a solid content;
(6d) subjecting the solid content obtained in step (6c) to delipidation treatment, and post-processing to obtain a solid content;
(6e) diluting the solid content obtained in step (6d) to obtain cell-free fat extract D.

### Claim 6 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (6), the emulsification treatment comprises homogenizing and emulsifying with a homogenizer, the emulsification treatment further comprises a step of centrifuging to separate the oil layer, and the emulsification treatment comprises one or more features selected from the group consisting of:
(1) the speed of the homogenizer is 5000-15000 r/min;
(2) the emulsification time is 0.5-15 minutes;
(3) the centrifugation is carried out at 1000-8000 r/min; and
(4) the centrifugation time is 2-20 minutes.

### Claim 7 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (6), the disinfection treatment comprises mixing with a disinfectant, oscillating and then discarding the liquid layer; and the disinfection treatment further comprises one or more features selected from the group consisting of:
(1) the disinfectant is a mixed solution of peracetic acid and ethanol, the concentration of peracetic acid is 0.05-3%, the concentration of ethanol is 1-24%;
(2) the mass ratio of the solid content obtained after emulsification treatment to the disinfectant is 1:1~1:20; and
(3) the oscillation treatment time is 0.5-6 hours.

### Claim 8 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (6), the decellularization treatment comprises mixing with a decellularizing agent, oscillating and then discarding the liquid layer; and the decellularization treatment further comprises one or more features selected from the group consisting of:
(1) the decellularizing agent is selected from the group consisting of SDS, TritonX-100, sodium deoxycholate, and combinations thereof;
(2) the concentration of the decellularizing agent is 0.2-5%;
(3) the mass ratio of the solid content obtained after disinfection treatment to the decellularizing agent is 1:1~1:20; and
(4) the oscillation treatment time is 12-96 hours.

### Claim 9 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein in step (6), the delipidation treatment comprises mixing with a degreaser, oscillating and then discarding the liquid layer; and the delipidation treatment further comprises one or more features selected from the group consisting of:
(1) the degreaser is selected from the group consisting of isopropanol, ethanol, ether, and combinations thereof;
(2) the mass ratio of the solid content obtained after decellularization treatment to the degreaser is 1:1~1:20; and
(3) the oscillation treatment time is 0.5-24 hours.

### Claim 10 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein step (7) comprises the following steps:
(7a) providing cell-free fat extract D as a form of lotion;
(7b) adding the fat extract C into the lotion obtained in step (7a), and mixing;
(7c) freeze-drying to obtain the decellularized adipose biomaterial.

### Claim 11 (depends on 1)

A method for preparing the decellularized adipose biomaterial according to claim 1, comprising the following steps:
(1) providing an adipose tissue raw material, crushing the adipose tissue raw material, and rinsing it to obtain a rinsed adipose tissue;
(2) subjecting the rinsed adipose tissue to centrifugation to obtain a layered mixture, removing the upper oil layer and the lower aqueous layer, and collecting the intermediate layer;
(3) subjecting the intermediate layer to emulsification to obtain an emulsified fat mixture;
(4) subjecting the emulsified fat mixture to centrifugation to obtain an intermediate liquid layer, which is the initial adipose extract A, and an intermediate solid layer, which is the initial adipose extract B;
(5) subjecting the initial adipose extract A to filtration and sterilization to obtain cell-free fat extract C;
(6) subjecting the initial adipose extract B to emulsification treatment, disinfection treatment, decellularization treatment, and delipidation treatment in sequence to obtain cell-free fat extract D;
(7) mixing the cell-free fat extract C with D and post-processing to obtain the decellularized adipose biomaterial.

### Claim 12 (depends on 1)

A tissue repair material comprising the decellularized adipose biomaterial according to claim 1.

### Claim 13 (depends on 1)

A use of the decellularized adipose biomaterial according to claim 1 for preparing a medical material or a medical aesthetic material, wherein the medical material is used for soft tissue repair, and the medical aesthetic material is used for plastic surgery and filling.

### Claim 14 (depends on 1)

A method for soft tissue repair, comprising administering the decellularized adipose biomaterial according to claim 1 to a subject in need thereof.

### Claim 15 (depends on 1)

A method for plastic surgery and filling, comprising administering the decellularized adipose biomaterial according to claim 1 to a subject in need thereof.

### Claim 16 (depends on 1)

A medical material comprising the decellularized adipose biomaterial according to claim 1, and pharmaceutically acceptable carriers.

### Claim 17 (depends on 1)

A medical aesthetic material comprising the decellularized adipose biomaterial according to claim 1, and acceptable carriers in the field of medical cosmetology.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the decellularized adipose biomaterial is administered by injection, orally, or topically.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the injection includes subcutaneous injection, intradermal injection, and intravenous injection.

### Claim 20 (depends on 1)

The decellularized adipose biomaterial according to claim 1, wherein the decellularized adipose biomaterial has one or more features selected from the group consisting of:
(1) after being filled into the body for 2 weeks, the quality retention rate is above 68%;
(2) after being filled into the body for 2 weeks, the volume retention rate is above 70%;
(3) after being filled into the body for 3 months, the quality retention rate is above 35%;
(4) after being filled into the body for 3 months, the volume retention rate is above 40%; and
(5) after being stored at 37° C. for 14 days, the protein release of the extracted solution is more than 15 μg/mL.
